Nephrol Dial Transplant (1999) 14: 2810-2812
© 1999 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Reversal of hyperhomocyst(e)inaemia in chronic renal failure—is folic or folinic acid the answer?
Division of Nephrology, C.H. Beauvais, and INSERM U 507, Necker Hospital, Paris, France
Correspondence and offprint requests to: Ziad A. Massy, MD, INSERM U 507, Necker Hospital, 161 rue de Sèvres, F-75730 Paris Cedex 15, France. E-mail: massy@citi2.fr.
Introduction
Moderate elevation of plasma total homocyst(e)ine (Hcy) concentration is present in the early stage of chronic renal failure (CRF), increases in parallel with the degree of reduction in renal function, and persists after starting dialysis [1,2]. In view of the potential athero-thrombogenic role of hyperhomocyst(e)inaemia, attempts have been made to lower plasma tHcy concentrations in CRF patients. Routine minimal folic acid supplementation of 1 mg daily, in contrast to what has been generally observed in the population at large, does not have an effect on plasma total Hcy concentration, despite a supernormal plasma folate level reached in CRF patients [3]. Even worse, the oral supplementation with high doses of folic acid (up to 15 mg daily), which leads to a 20- to 50-fold increase of plasma folate concentrations, is
Folate metabolism in normal subjects
Folate metabolism in chronic renal failure
Conclusion
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. L. Moens, C. J. Vrints, M. J. Claeys, J.-P. Timmermans, H. C. Champion, and D. A. Kass Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1971 - H1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Buccianti, S. Raselli, I. Baragetti, F. Bamonti, E. Corghi, C. Novembrino, C. Patrosso, F. M. Maggi, and A. L. Catapano 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis Nephrol. Dial. Transplant., May 1, 2002; 17(5): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, J. Bommer, G. M. London, A. Martin-Malo, C. Wanner, M. Yaqoob, and C. Zoccali Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment Nephrol. Dial. Transplant., March 1, 2001; 16(3): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Suliman, J. C. D. Filho, P. Barany, B. Anderstam, B. Lindholm, and J. Bergstrom Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2001; 16(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Bostom, D. Shemin, P. Bagley, Z. A. Massy, A. Zanabli, K. Christopher, P. Spiegel, P. F. Jacques, L. Dworkin, and J. Selhub Controlled Comparison of L-5-Methyltetrahydrofolate Versus Folic Acid for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients Circulation, June 20, 2000; 101(24): 2829 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bennett-Richards, M. Kattenhorn, A. Donald, G. Oakley, Z. Varghese, L. Rees, and J.E. Deanfield Does Oral Folic Acid Lower Total Homocysteine Levels and Improve Endothelial Function in Children With Chronic Renal Failure? Circulation, April 16, 2002; 105(15): 1810 - 1815. [Abstract] [Full Text] [PDF]
|
|